Breast Cancer Research and Treatment

, Volume 137, Issue 3, pp 903–913

Supplement use during an intergroup clinical trial for breast cancer (S0221)

  • Gary R. Zirpoli
  • Patrick M. Brennan
  • Chi-Chen Hong
  • Susan E. McCann
  • Gregory Ciupak
  • Warren Davis
  • Joseph M. Unger
  • G. Thomas Budd
  • Dawn L. Hershman
  • Halle C.F. Moore
  • James Stewart
  • Claudine Isaacs
  • Timothy Hobday
  • Muhammad Salim
  • Gabriel N. Hortobagyi
  • Julie R. Gralow
  • Kathy S. Albain
  • Christine B. Ambrosone
Open AccessEpidemiology

DOI: 10.1007/s10549-012-2400-2

Cite this article as:
Zirpoli, G.R., Brennan, P.M., Hong, C. et al. Breast Cancer Res Treat (2013) 137: 903. doi:10.1007/s10549-012-2400-2

Abstract

The use of supplements during chemotherapy is controversial, partly due to the potential effect of antioxidants on reduced efficacy of chemotherapy-related cytotoxicity. We examined supplement use among breast cancer patients registered to a clinical trial (SWOG 0221) before diagnosis and during treatment. Patients (n = 1,467) completed questionnaires regarding multivitamin and supplement use at trial registration (baseline) to capture use before diagnosis. Of these patients, 1,249 completed a 6-month followup questionnaire to capture use during treatment. We examined the use of vitamins C, D, E, B6, B12, folic acid, and calcium at these timepoints, as well as physician recommendations regarding supplement use. The use of vitamins C, E, folic acid, and calcium decreased during treatment, while the use of vitamin B6 increased. Five hundred seventy four patients (51 %) received no physician recommendations regarding supplement use. Among the remaining 49, 10 % were advised not to take multivitamins and/or supplements, 7 % were advised to use only multivitamins, and 32 % received recommendations to use multivitamins and/or supplements. Among patients who took vitamin C before diagnosis, those who were advised not to take supplements were >5 times more likely not to use of vitamin C during treatment than those not advised to stop use (OR = 5.27, 95 % CI 1.13–24.6). Previous non-users who were advised to take a multivitamin were nearly 5 times more likely to use multivitamins during treatment compared to those who received no recommendation (OR = 4.66, 95 % CI 2.10–10.3). In this clinical trial for high-risk breast cancer, supplement use generally decreased during treatment. Upon followup from the clinical trial, findings regarding supplement use and survival outcomes will better inform physician recommendations for patients on adjuvant chemotherapy.

Keywords

AntioxidantsDietary supplementsEpidemiologyBreast cancerChemotherapy

Introduction

Dietary supplement use is widespread among adults in the United States [1], and has been increasing over time [2]. Supplement use is especially prevalent among breast cancer patients. In the Women’s Healthy Eating and Living study, 58 % of the breast cancer survivors who participated reported use of multivitamins with 46 and 42 % reporting use of vitamins E and C, respectively [3, 4]. In the long Island breast cancer study project (LIBCSP), 60 % of patients reported using antioxidant supplements during adjuvant treatment [5]. Breast cancer patients have also been shown to take dietary supplements at dosages well above the recommended daily allowances [4, 5].

There is controversy surrounding the use of antioxidant supplements during therapy for cancer, particularly because of their potentially negative effects on treatment efficacy. As previously reviewed [6], a primary mechanism of cytotoxicity for numerous chemotherapy agents, as well as radiation therapy, is through generation of reactive oxygen species (ROS), which damage and kill tumor as well as normal cells. Because antioxidants can reduce ROS and potentially reduce treatment efficacy, it has been recommended that physicians discourage their patients from use of antioxidant supplements during treatment [7]. The American Institute for Cancer Research states that “taking dietary supplements containing levels of nutrients with antioxidant properties much greater than the dietary reference intakes is not recommended during chemotherapy” [8, 9], and a 2005 Journal of Clinical Oncology commentary from a large comprehensive cancer center discloses that their patients are discouraged from taking supplements during cancer treatment [10]. However, there are also reports that antioxidants may reduce chemotherapy-induced neurotoxicity and cardiotoxicity [6]. In addition, in the life after cancer epidemiology (LACE) Study, breast cancer patients frequently using vitamin C and vitamin E had fewer recurrences and a reduced risk of mortality, but an increased risk of death with frequent carotenoid use [11].

Although supplement use appears to be common among cancer patients, many patients do not discuss supplement use with physicians. Estimates of percentages of patients who report supplement use to their physicians range from as low as 33 % to up to 82 % of patients [1215]. In addition, studies have indicated that the extent to which health care providers communicate with patients about supplement use is low with lack of confident knowledge on the subject a major contributing factor [16, 17].

In this report, we present the characteristics of patients enrolled in an observational study ancillary to a large cooperative group therapeutic trial for women with high-risk breast cancer. With data collected regarding previous habits, use at registration, and again following completion of treatment, this trial provides an ideal basis for examining the use of vitamin supplements before diagnosis and during chemotherapy, and the extent to which discussions with patients’ physicians influenced patterns of usage during treatment.

Methods

Patients

This study was conducted ancillary to a North American Breast Cancer Group phase III trial (S0221) led by SWOG, formerly Southwest Oncology Group. Eligibility criteria for S0221 included confirmed diagnosis of operable Stage II or III invasive breast cancer with known estrogen or progesterone receptor status, high-risk status based on tumor size or nodal involvement, a history of modified radical mastectomy or local excision of all tumors plus axillary node dissection or sentinel node resection, and no previous history of chemotherapy or radiation. Criteria also included normal blood work, age 18+, Zubrod performance status of 0–2, as well as a medical history free of heart failure, angina, HIV, and previous malignancies.

As shown in Fig. 1, patients enrolled in the trial were randomized to four treatment arms. Each arm utilized the same 3 drugs, but followed a different treatment schedule. Patients received either doxorubicin plus cyclophosphamide every 2 weeks with pegfilgrastim support, or weekly doxorubicin plus daily cyclophosphamide with filgrastim support. Patients then received either 12 cycles of weekly paclitaxel or paclitaxel every 2 weeks with pegfilgrastim support for 6 cycles.
https://static-content.springer.com/image/art%3A10.1007%2Fs10549-012-2400-2/MediaObjects/10549_2012_2400_Fig1_HTML.gif
Fig. 1

Design of SWOG 0221, a trial for women with high-risk breast cancer A doxorubicin, C cyclophosphamide, G filgrastim, PEGG pegfilgrastim, T paclitaxel

This ancillary study regarding effects of lifestyle factors on treatment outcomes was described in the therapeutic consent for the trial, and informed consent included permission to contact the patient. Upon agreement to participate, patients’ contact information was forwarded to research study staff for followup with the potential participants. This study ancillary to S0221 was approved by the Institutional Review Board at Roswell Park Cancer Institute, and at all participating institutions that enrolled patients.

Study design

The long-term goal of this prospective ancillary study, the diet, exercise, lifestyle, and cancer prognosis (DELCaP) study, is to determine if habits and practices before and during chemotherapy have any impact on treatment outcomes, including treatment-related toxicities as well as recurrence and survival. For this purpose, patients are contacted at registration to the trial, the DELCaP study is described in more detail, and a questionnaire is sent to the participants. This baseline questionnaire gathers data on race and ethnicity, menopausal status, height and weight, histories of smoking, alcohol consumption, and physical activity. A 110-item Food Frequency Questionnaire and detailed data on use of vitamins and supplements are also collected via questions adapted from the VITAL study, which has been extensively validated [18]. Participants are asked to gather all multivitamins and supplements they are taking. For multivitamins, patients may choose from a predefined list of popular brands of multivitamin (Centrum, etc.) or may fill in the specific brand they use, as well as the number of days of use and the number of years taken in the past 10. Patients are then queried for dosages of select multivitamin components. For individual supplement use, frequency of use and daily dose are recorded.

At 6 months after registration to the trial, when chemotherapy should be completed, a second questionnaire is mailed to participants. This questionnaire has the same general format as the first, and updates lifestyle factors and supplement use during treatment. It also includes a section on recommendations received from the patient’s physicians, and queries if the use of vitamins and supplements during treatment was discussed and if the participants’ doctors made any recommendations. If recommendations were received, patients are further queried regarding suggestions (Fig. 2). Additional questionnaires are sent annually soliciting the same information on lifestyle factors for eventual analysis in relation to recurrence and survival.
https://static-content.springer.com/image/art%3A10.1007%2Fs10549-012-2400-2/MediaObjects/10549_2012_2400_Fig2_HTML.gif
Fig. 2

Question at completion of chemotherapy regarding physician recommendations on supplement use during treatment

All questionnaires were entered twice by different data entry personnel. This analysis includes 1,467 participants who completed the baseline questionnaire; of these women, we include data from 1,249 patients who also completed the 6-month questionnaire. Two hundred eighteen participants withdrew from the study between the first questionnaire and the second questionnaire. These participants were younger, less likely to be non-Hispanic white, were more likely to have smoked, and had lower education.

Statistical analysis

The focus of this analysis is on use of vitamin supplements before diagnosis and during treatment for breast cancer, and in relation to physician recommendations. In the first questionnaire, patients were asked if they took supplements before breast cancer diagnosis and/or, if they took supplements after diagnosis (No; Yes, but less than once a week; Yes, at least once a week). In the second questionnaire, participants were asked if they took supplements during treatment. Those who responded that they used supplements at least once per week were classified as “users.” “Non-users” were those who did not use at all, or used less than once per week. Because of the low rates of use of other supplements, we present data only on supplements with at least 10 % use at any time point. For all analyses presented, we compared supplement use before diagnosis to supplement use during treatment. Although physician recommendations were not queried until the second questionnaire, it is possible that physician recommendations at diagnosis influenced supplement use during the period between diagnosis and treatment. Thus, we compared use before diagnosis and 6 months following entry into the trial.

Answers regarding physician recommendations were categorized into “No recommendation,” “Do not use vitamins and/or supplements during treatment,” “Use a multivitamin only,” and “Use vitamins and supplements during and after treatment.” Participants also had the option to write in their physician’s recommendations, instead of choosing from the predefined list. These answers were hand-coded and grouped into one of the first three categories. Of these, written answers from 115 participants could not be classified into any of the categories.

For each supplement, participants were stratified by use before diagnosis into baseline users and non-users. For baseline users, unconditional logistic regression was used to estimate odds ratios (OR) and 95 % confidence intervals (CI) for the association between discontinuing use during treatment and physician recommendations. Analogous analyses for baseline non-users were conducted to model the association between beginning use during treatment and physician recommendations. Self-reported height and usual weight before diagnosis were used to compute body mass index (BMI) in kilograms/meters2. ORs and 95 % CIs were calculated and adjusted for age at completion of the first questionnaire, BMI, race/ethnicity, education level, menopausal status, and smoking status (never/former/current). All analyses were conducted by SAS 9.2.

Results

The baseline characteristics of 1,467 breast cancer patients who completed the first questionnaire are shown in Table 1. The mean age at baseline was 51 years (range: 23–80 years); 80 % of participants identified themselves as non-Hispanic white and the majority of patients (71 %) were overweight or obese. Slightly more than half were postmenopausal. More than half (56 %) were never smokers, 72 % had at least some college, and the majority were married or living as married (73 %).
Table 1

Characteristics of 1,467 DELCaP participants

Characteristic

N (%)

Age

 <35

63 (4.3)

 35–39

109 (7.4)

 40–44

195 (13.3)

 45–49

276 (18.8)

 50–54

277 (18.9)

 55–59

225 (15.3)

 60–64

174 (11.9)

 65–69

100 (6.8)

 ≥70

48 (3.3)

Race

 Non-hispanic white

1,176 (80.2)

 Hispanic

65 (4.4)

 Black/African American

104 (7.1)

 Other

122 (8.3)

BMI

 Underweight (≤18.5)

12 (0.8)

 Normal (18.5–24.9)

412 (28.4)

 Overweight (25–29.9)

469 (32.4)

 Obese (≥30)

556 (38.4)

Menopausal status

 Premenopausal

686 (46.8)

 Postmenopausal

781 (53.2)

Smoking history

 Never smokers

806 (55.5)

 Former smokers

461 (31.7)

 Current smokers

186 (12.8)

Education

 Grade school or some high school

97 (6.6)

 High school graduate or GED

311 (21.3)

 Some college or technical school

522 (35.8)

 College graduate

325 (22.3)

 Advanced degree

205 (14.0)

Marital status

 Married or living as married

1,067 (73.1)

 Widowed

68 (4.6)

 Separated or Divorced

236 (16.2)

 Single

89 (6.1)

Supplements with usage of at least 10 % of the study population either before diagnosis, or during treatment for breast cancer, are displayed in Table 2. Multivitamins were the supplements used most frequently with 48 % use before diagnosis and 43 % use during treatment. Other supplements that showed decreases in use during treatment included vitamin C (20 % before diagnosis vs. 12 % during treatment), vitamin E (15 vs. 6 %), folic acid (10 vs. 8 %), calcium (34 vs. 28 %), fish oil, EPA, omega-3, flaxseed or cod liver oil (22 vs. 12 %), and glucosamine (13 vs. 7 %). Compared to before diagnosis, vitamin B6 use increased during treatment (10 vs. 19 %).
Table 2

Supplement use before and during breast cancer treatment

Supplement use before diagnosis

Supplement use during treatment

Total

Pa

No

Yes

N (%)

N (%)

N (%)

Multivitamin

 No

510 (41.2)

133 (10.7)

643 (51.9)

0.0009

 Yes

193 (15.6)

402 (32.5)

595 (48.1)

 Total

703 (56.8)

535 (43.2)

1,238 (100)

Vitamin C

 No

931 (75.2)

62 (5.0)

993 (80.2)

<.0001

 Yes

160 (12.9)

85 (6.9)

245 (19.8)

 Total

1,091 (88.1)

147 (11.9)

1,238 (100)

Vitamin D

 No

795 (64.2)

155 (12.5)

950 (76.7)

0.1229

 Yes

129 (10.4)

160 (12.9)

289 (23.3)

 Total

924 (74.6)

315 (25.4)

1,239 (100)

Vitamin E

 No

1,005 (81.2)

42 (3.4)

1,047 (84.6)

<.0001

 Yes

154 (12.4)

37 (3.0)

191 (15.4)

 Total

1,159 (93.6)

79 (6.4)

1,238 (100)

Vitamin B6

 No

933 (75.4)

186 (15.0)

1,119 (90.4)

<.0001

 Yes

69 (5.6)

50 (4.0)

119 (9.6)

 Total

1,002 (80.9)

236 (19.1)

1238 (100)

Folic Acid

 No

1,051 (84.8)

62 (5.0)

1,113 (89.8)

0.0231

 Yes

90 (7.3)

37 (3.0)

127 (10.2)

 Total

1,141 (92)

99 (8)

1,240 (100)

Vitamin B12

 No

999 (80.5)

82 (6.6)

1,081 (87.1)

0.2622

 Yes

97 (7.8)

63 (5.1)

160 (12.9)

 Total

1,096 (88.3)

145 (11.7)

1,241 (100)

Calcium

 No

695 (56.0)

119 (9.6)

814 (65.6)

<.0001

 Yes

198 (16.0)

229 (18.4)

427 (34.4)

 Total

893 (72)

348 (28)

1,241 (100)

Fish oil, EPA, omega-3, flaxseed or cod liver oil

 No

907 (73.5)

47 (3.8)

954 (77.3)

<.0001

 Yes

172 (13.9)

108 (8.8)

280 (22.7)

 Total

1,079 (87.4)

155 (12.6)

1,234 (100)

Glucosamine

 No

1,059 (85.7)

18 (1.5)

1,077 (87.1)

<.0001

 Yes

97 (7.8)

62 (5.0)

159 (12.9)

 Total

1,156 (93.5)

80 (6.5)

1,236 (100)

aMcNemar’s test comparing the differences in use before and during treatment

Average supplement doses per day before diagnosis and during breast cancer treatment are presented in Table 3. After diagnosis and during treatment, vitamin D use increased overall among those women in the middle and highest categories of use with a concomitant decrease in the lowest category of use. As expected, use of higher doses of vitamin B6 (13+ mg/day) increased markedly during treatment, from 50 % before diagnosis to 87 % during treatment. While overall use of B12 decreased slightly between during breast cancer treatment, the percentage of high average daily dosage (24+ μg/day) increased from 67 % before diagnosis to 84 % during treatment. Calcium use was largely unchanged from before diagnosis to during treatment. Iron intake increased during treatment in the lowest and highest categories, but decreased for the middle category. There were no clear trends for vitamins C and E.
Table 3

Average supplement dose per day before and during breast cancer treatment

Supplement

Time period

Before diagnosis

During treatment

N (%)

N (%)

Vitamin C (mg/day)

 <75

19 (8)

15 (10.3)

 75–750

142 (59.9)

81 (55.9)

 750+

76 (32.1)

49 (33.8)

Vitamin D (μg/day)

 <15

147 (52.3)

137 (44.9)

 15–150

129 (45.9)

158 (51.8)

 150+

5 (1.8)

11 (3.6)

Vitamin E (mg/day)

 <15

1 (0.6)

4 (5.1)

 15–150

64 (36.8)

29 (37.2)

 150+

109 (62.6)

45 (57.7)

Vitamin B6 (mg/day)

 <1.3

3 (2.8)

1 (0.5)

 1.3–13

51 (47.7)

27 (12.3)

 13+

53 (49.5)

191 (87.2)

Folic acid (μg/day)

 <400

38 (34.2)

28 (30.1)

 400+

73 (65.8)

65 (69.9)

Vitamin B12 (μg/day)

 <2.4

0

0

 2.4–24

47 (33.3)

22 (15.9)

 24+

94 (66.7)

116 (84.1)

Calcium (mg/day)

 <1000

265 (65.4)

232 (66.1)

 1000+

140 (34.6)

119 (33.9)

Table 4 shows data collected from the 2nd questionnaire administered at 6 months related to physician recommendations regarding supplement use. Five hundred seventy four patients (51 %) received no recommendation (either due to no discussion of supplement use with their doctors, or did discuss, but received no specific recommendations). Among the remaining 560 participants who did receive recommendations, 112 received recommendations not to take multivitamins and/or supplements (10 %), 80 received recommendations to use only multivitamins (7 %), and 368 received recommendations to use multivitamins and/or supplements (32 %).
Table 4

Patient-reported physician recommendations on vitamin and supplement use during treatment

Physician recommendation

N (%)

No recommendation

574 (50.6)

Do not use vitamins or supplements during treatment

112 (9.9)

Use a multivitamin only

80 (7.1)

Use vitamins and supplements during and after treatment

368 (32.4)

Unable to be classified

115

Multivitamin and supplement use during treatment among baseline users

Multivitamin and supplement use during treatment was compared to use before diagnosis in relation to physician recommendations with the reference group comprised of those receiving no recommendations. Models for baseline multivitamin and supplement users adjusted for age at baseline alone and additionally adjusted for BMI at baseline, race/ethnicity, education level, menopausal status, and smoking status are presented in Table 5. Among those using multivitamins at least once per week at baseline, patients receiving recommendations not to take multivitamins and/or supplements were 45 times more likely to reduce multivitamin use to less than once per week during treatment, compared to those receiving no recommendations (adjusted odds ratio (aOR) = 45.0, 95 % CI 10.6–191). Patients who were advised to use multivitamins only were less likely to decrease use than those receiving no recommendations (aOR = 0.21, 95 % CI 0.08–0.6), as were patients receiving recommendations to use multivitamins and/or supplements (aOR = 0.46, 95 % CI 0.29–0.72).
Table 5

Odds of discontinuing supplement use during treatment among baseline multivitamin and antioxidant supplement users, according to physician recommendations

Physician advice

Usage during treatmenta

% Who stop use

ORb (95 % CI)

ORc (95 % CI)

Multivitamin supplement use >1/week at baseline (N = 542)

 No recommendation

33 % (81/243)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

96 % (47/49)

45.0 (10.6–191)

44.7 (10.5–190)

 Use a multivitamin only

10 % (5/49)

0.21 (0.08–0.56)

0.22 (0.08–0.60)

 Use vitamins and supplements

18 % (37/201)

0.44 (0.28–0.69)

0.46 (0.29–0.72)

Vitamin C supplement use >1/week at baseline (N = 214)

 No recommendation

60 % (55/91)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

100 % (28/28)

NA

NA

 Use a multivitamin only

91 % (20/22)

5.99 (1.31–27.5)

5.27 (1.13–24.6)

 Use vitamins and supplements

51 % (37/73)

0.69 (0.36–1.29)

0.72 (0.37–1.39)

Vitamin D supplement use >1/week at baseline (N = 259)

 No recommendation

47 % (53/112)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

72 % (18/25)

2.76 (1.06–7.24)

2.61 (0.97–6.99)

 Use a multivitamin only

58 % (11/19)

1.48 (0.54–4.08)

1.39 (0.48–3.99)

 Use vitamins and supplements

36 % (37/103)

0.66 (0.38–1.16)

0.65 (0.37–1.16)

Vitamin E supplement use >1/week at baseline (N = 169)

 No recommendation

79 % (59/75)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

100 % (21/21)

NA

NA

 Use a multivitamin only

94 % (16/17)

3.74 (0.45–30.8)

3.52 (0.40–31.3)

 Use vitamins and supplements

70 % (39/56)

0.58 (0.26–1.30)

0.48 (0.20–1.17)

Vitamin B6 supplement use >1/week at baseline (N = 102)

 No recommendation

62 % (26/42)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

90 % (9/10)

5.50 (0.62–49.1)

11.0 (0.95–126)

 Use a multivitamin only

75 % (9/12)

1.06 (0.22–5.00)

1.86 (0.25–14.0)

 Use vitamins and supplements

42 % (16/38)

0.36 (0.14–0.93)

0.30 (0.09–0.98)

Folic acid supplement use >1/week at baseline (N = 111)

 No recommendation

72 % (31/43)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

100 % (13/13)

NA

NA

 Use a multivitamin only

89 % (8/9)

3.01 (0.33–27.1)

3.04 (0.30–31.2)

 Use vitamins and supplements

61 % (28/46)

0.65 (0.26–1.60)

0.66 (0.24–1.80)

Vitamin B12 supplement use >1/week at baseline (N = 143)

 No recommendation

58 % (36/62)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

91 % (10/11)

7.48 (0.88–63.2)

7.83 (0.91–67.1)

 Use a multivitamin only

64 % (7/11)

1.01 (0.25–4.03)

1.17 (0.27–5.11)

 Use vitamins and supplements

56 % (33/59)

0.89 (0.43–1.87)

0.87 (0.40–1.91)

Calcium supplement use >1/week at baseline (N = 388)

 No recommendation

53 % (87/165)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

83 % (34/41)

4.22 (1.77–10.1)

4.15 (1.70–10.1)

 Use a multivitamin only

47 % (16/34)

0.78 (0.37–1.64)

0.93 (0.43–2.00)

 Use vitamins and supplements

33 % (49/148)

0.44 (0.28–0.70)

0.48 (0.30–0.77)

Fish oil, EPA, omega-3, flaxseed, or cod liver oil use >1/week at baseline (N = 242)

 No recommendation

57 % (64/113)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

97 % (31/32)

24.5 (3.22–187)

25.3 (3.30–195)

 Use a multivitamin only

67 % (12/18)

1.66 (0.57–4.81)

1.47 (0.49–4.37)

 Use vitamins and supplements

47 % (37/79)

0.72 (0.40–1.29)

0.72 (0.39–1.33)

Glucosamine supplement use >1/week at baseline (N = 142)

 No recommendation

58 % (35/60)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

95 % (19/20)

11.8 (1.47–95.1)

12.3 (1.48–102)

 Use a multivitamin only

73 % (8/11)

1.77 (0.42–7.50)

1.64 (0.37–7.22)

 Use vitamins and supplements

47 % (24/51)

0.60 (0.28–1.30)

0.61 (0.27–1.36)

aContinue use defined as those consuming the supplement ≥ once per week; Stop use are those consuming the supplement < once per week

bAdjusted for age at baseline

cAdjusted for age at baseline, body mass index at baseline, race/ethnicity, education, menopausal status, and smoking status

Among those using vitamin C supplements at least once per week at baseline, all patients receiving recommendations not to take multivitamins and/or supplements decreased use of vitamin C to less than once per week. Patients who were told to use multivitamins only were over 5 times more likely to decrease use of vitamin C, compared to those receiving no recommendations (aOR = 5.27, 95 % CI = 1.13–24.6). Compared to those receiving no advice, participants receiving recommendations to use multivitamins and/or supplements during treatment were less likely to decrease vitamin C use to less than once per week although this difference was not statistically significant (aOR = 0.72, 95 % CI = 0.37–1.39).

Among those using vitamin E supplements at least once per week at baseline, all patients receiving recommendations not to take multivitamins and/or supplements decreased use of vitamin E to less than once per week. Those receiving recommendations to use multivitamins only were 3.5 times as likely to decrease vitamin E use to less than once per week compared to those receiving no recommendations (aOR = 3.52, 95 % CI 0.40–31.3). Patients receiving recommendations to use multivitamins and/or supplements during treatment were less likely to decrease use of vitamin E to less than once per week than those receiving no recommendations (aOR = 0.48, 95 % CI 0.20–1.17).

Use of the other supplements assessed showed similar trends in patterns of use although there were small numbers for some subgroups. Fish oil and glucosamine users at baseline, in particular, who received recommendations to not use vitamins or supplements were much more likely to stop usage, compared to those receiving no recommendation (aOR = 25.3, 95 % CI 3.30–195; aOR = 12.3, 95 % CI 1.48–102, respectively).

Multivitamin and/or supplement use during treatment among non-users

Analogous models for baseline non-users of multivitamins and/or supplements are presented in Table 6. Multivitamin use during treatment among previous non-users increased among those whose physicians recommended multivitamin use only during treatment (aOR = 4.66, 95 % CI 2.10–10.3). Few participants who were non-users of vitamin C or vitamin E at baseline began using these vitamins during treatment (6 and 5 %, respectively), regardless of recommendations received. For non-users of vitamin C at baseline, participants receiving recommendations to use vitamins and supplements during treatment were twice as likely to use vitamin C during treatment (aOR = 1.82, 95 % CI 0.99–3.33); similar associations were observed for vitamin E (aOR = 4.59, 95 % CI 2.10–10.0). Baseline non-users of vitamin D receiving recommendations to use vitamins and supplements were nearly four times more likely to start vitamin D use than those receiving no recommendation (aOR = 3.86, 95 % CI 2.55–5.86). Similar associations were observed in vitamins B6 and B12 (aOR = 6.39, 95 % CI 4.24–9.62; aOR = 5.10, 95 % CI 2.78–9.37, respectively).
Table 6

Odds of supplement usage during treatment among non-users of multivitamin and antioxidant supplements at baseline, according to physician recommendations

Physician advice

Usage during treatmenta

ORb (95 % CI)

ORc (95 % CI)

% Who start use

Multivitamin supplement non-users (N = 583)

 No recommendation

14 % (45/327)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

8 % (5/62)

0.55 (0.21–1.43)

0.54 (0.21–1.44)

 Use a multivitamin only

43 % (13/30)

4.74 (2.15–10.4)

4.66 (2.10–10.3)

 Use vitamins and supplements

37 % (61/164)

3.70 (2.37–5.79)

3.59 (2.28–5.66)

Vitamin C supplement non-users (N = 910)

 No recommendation

5 % (23/475)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

4 % (3/84)

0.74 (0.22–2.54)

0.87 (0.25–3.03)

 Use a multivitamin only

3 % (2/58)

0.70 (0.16–3.06)

0.69 (0.16–3.05)

 Use vitamins and supplements

9 % (26/293)

1.92 (1.07–3.43)

1.82 (0.99–3.33)

Vitamin D supplement non-users (N = 866)

 No recommendation

10 % (44/454)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

5 % (4/87)

0.46 (0.16–1.33)

0.47 (0.16–1.34)

 Use a multivitamin only

10 % (6/61)

1.03 (0.42–2.53)

0.93 (0.38–2.31)

 Use vitamins and supplements

30 % (79/264)

4.08 (2.71–6.15)

3.86 (2.55–5.86)

Vitamin E supplement non-users (N = 956)

 No recommendation

2 % (9/493)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

3 % (3/91)

1.75 (0.46–6.61)

1.73 (0.45–6.64)

 Use a multivitamin only

0 % (0/63)

NA

NA

 Use vitamins and supplements

9 % (27/309)

5.18 (2.4–11.2)

4.59 (2.10–10.0)

Vitamin B6 supplement non-users (N = 1023)

 No recommendation

7 % (38/526)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

15 % (15/102)

2.26 (1.19–4.29)

2.40 (1.25–4.59)

 Use a multivitamin only

7 % (5/67)

1.04 (0.39–2.73)

0.98 (0.37–2.60)

 Use vitamins and supplements

33 % (109/328)

6.41 (4.29–9.59)

6.39 (4.24–9.62)

Folic acid supplement non-users (N = 1016)

 No recommendation

3 % (18/525)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

2 % (2/99)

0.60 (0.14–2.62)

0.59 (0.13–2.61)

 Use a multivitamin only

3 % (2/71)

0.83 (0.19–3.64)

0.85 (0.19–3.75)

 Use vitamins and supplements

9 % (30/321)

2.94 (1.61–5.37)

2.88 (1.56–5.33)

Vitamin B12 supplement non-users (N = 984)

 No recommendation

3 % (16/507)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

4 % (4/101)

1.30 (0.42–3.98)

1.31 (0.42–4.07)

 Use a multivitamin only

4 % (3/69)

1.40 (0.40–4.93)

1.39 (0.39–4.95)

 Use vitamins and supplements

14 % (43/307)

5.02 (2.77–9.10)

5.10 (2.78–9.37)

Calcium supplement non-users (N = 739)

 No recommendation

9 % (38/403)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

7 % (5/71)

0.77 (0.29–2.03)

0.80 (0.30–2.13)

 Use a multivitamin only

7 % (3/46)

0.70 (0.21–2.36)

0.65 (0.19–2.23)

 Use vitamins and supplements

27 % (60/219)

3.80 (2.42–5.98)

3.56 (2.24–5.66)

Fish oil, EPA, omega-3, flaxseed or cod liver oil non-users (N = 880)

 No recommendation

4 % (18/452)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

3 % (2/79)

0.61 (0.14–2.67)

0.72 (0.16–3.23)

 Use a multivitamin only

3 % (2/62)

0.79 (0.18–3.48)

0.74 (0.17–3.31)

 Use vitamins and supplements

7 % (21/287)

1.89 (0.99–3.61)

1.91 (0.99–3.69)

Glucosamine supplement non-users (N = 982)

 No recommendation

1 % (6/508)

1.0 (ref)

1.0 (ref)

 Do not use vitamins or supplements

1 % (1/91)

0.89 (0.11–7.47)

0.78 (0.09–6.71)

 Use a multivitamin only

1 % (1/69)

1.20 (0.14–10.1)

1.21 (0.14–10.4)

 Use vitamins and supplements

3 % (9/314)

2.46 (0.87–6.98)

2.36 (0.82–6.76)

aStarted use defined as those consuming the supplement ≥ once per week; Continued non-use are those consuming the supplement < once per week

bAdjusted for age at baseline

cAdjusted for age at baseline, body mass index at baseline, race/ethnicity, education, menopausal status, and smoking status

Discussion

Our analyses of multivitamin and supplement use during chemotherapy by women enrolled in this clinical trial for high-risk breast cancer indicate that, in general, supplement use decreased during chemotherapy. However, use of vitamin B6 increased, and while the percentage of vitamin B12 users decreased slightly, more users reported vitamin B12 use at a high dosage during treatment than before diagnosis, perhaps to alleviate side effects of chemotherapy including neuropathy and anemia. Use of vitamin D also increased during treatment.

Supplement use in our study differed from previously published results. It has been reported that approximately 45–80 % of breast cancer patients in the United States use antioxidant supplements, including during treatment [19]. In the LIBCSP, 60.5 % of breast cancer patients reported using supplements during treatment, and 38 % reported using antioxidants during chemotherapy [5]. Of antioxidant users, 69 % used doses higher than those contained in a multivitamin. In our study of participants in a Cooperative Group clinical trial, the use of supplements was much lower at baseline (20 % used vitamin C at least once per week, 15 % used vitamin E at least once per week) and particularly lower during the course of chemotherapy (12 % used vitamin C at least once per week, 8 % used vitamin E at least once per week). This unexpected finding of low use at baseline could be due to temporal changes in awareness with growing publicity and recommendations that supplements may reduce treatment efficacy. The source populations may differ as well. Participants in both the LIBCSP and LACE studies were older on average than participants in our study (58.3 and 56.3 years versus 51.3, respectively) [5, 11]. Women were enrolled onto S0221 at sites throughout the country, from large metropolitan cancer centers to community oncology group programs in more rural areas, which may suggest that our sample is more representative of the general population in the U.S. Supplement use may be lower because the patients in this study had high-risk breast cancer, and may be less willing to use something with unknown effects on cancer therapy.

Despite the body of data from laboratory and preclinical studies demonstrating that supplements may interfere with chemotherapeutic efficacy, it is still unclear if use of supplements during treatment has any effect on therapeutic outcomes, as few data are available. In a prospective study of 1,038 patients with stage III colon cancer enrolled in the NCI-sponsored Cancer and Leukemia Group B, Ng and colleagues found no significant survival benefit to multivitamin use during treatment [20]. In a review of 22 peer-reviewed studies, Greenlee et al. [19] concluded that “findings did not support any conclusions regarding the effects of individual antioxidant supplements during conventional breast cancer treatment on toxicities, tumor response, recurrence, or survival.” Data from the Shanghai Breast Cancer Survival Study, a large cohort of breast cancer patients with 532 recurrences and 444 deaths, showed that use of vitamin E, vitamin C and multivitamins by breast cancer patients was associated with reduced risk of recurrence and survival, regardless of whether use was during chemotherapy or not [21]. Because dietary and lifestyle factors may differ between populations, it is unclear as to whether these findings would apply to a mainly white, U.S. population.

There are some limitations in our assessment of physician recommendations. We were unable to discern whether discussions regarding multivitamin and/or supplement use were initiated by physicians or by patients. In addition, the question regarding recommendations from physicians only referred to vitamins and supplements in general, not specific supplements such as antioxidants or those that showed increases in use with chemotherapy. Furthermore, it did not distinguish use of high-dose supplements versus meeting recommended daily requirements. While a recommendation not to take any vitamins and supplements would include antioxidants, a recommendation to use vitamins and supplements may refer to other supplements than antioxidants, such as B vitamins for neuropathy. However, baseline non-users of vitamin C and E were more likely to initiate use during treatment after receiving a recommendation to use vitamins and supplements compared to those receiving no recommendation. In this study, regular vitamin C and E use, both before diagnosis and during treatment, was relatively low. When stratified by physician recommendation, sample sizes for some groups were small.

We have shown that patterns of use in this study are impacted greatly by physician recommendations. The participants in this clinical trial had “high-risk” Stage II or III breast cancer with large tumors and/or nodal involvement. Patients who enroll in a clinical trial may have more concerns about their prognosis, or may have more reliance upon or confidence in their oncologists, and this could influence the lower use than that reported in the literature. Indeed, our results show that supplement use was most likely to be stopped when patients were advised by their physicians to discontinue use. To our knowledge, this is the first study to report upon patterns of supplement use during chemotherapy in relation to recommendations from treating physicians, and the first survey of these interactions between cancer patients and their doctors. Thus, we are unable to compare our low rates of use of supplements in relation to physician recommendations to other published data on antioxidant use among breast cancer patients. A major strength of our study is the detailed assessment of multivitamin and supplement use at multiple time points, specifically before diagnosis and during breast cancer treatment. The majority of studies reporting on supplement use by cancer patients are derived from data ascertained at diagnosis, or several months following treatment, with little information on patterns during chemotherapy, which could be the most crucial time-point for effects on treatment outcomes.

In this study, a number of participants did not discuss supplement usage with their doctors. This would suggest that better patient-physician communication is needed although there are not clear empirical data upon which to base suggestions regarding habits during chemotherapy. With adequate followup time of patients enrolled in S0221, and detailed information on use of multivitamins and supplements before, during and after chemotherapy, data upon which to base those recommendations will be available for advising patients on habits during cancer therapy.

Acknowledgments

We wish to acknowledge and thank Dr. Frank L. Meyskens, Jr., M.D., Associate Chair for the Cancer Control & Prevention Committees of SWOG, for his administrative support.

Conflict of interest

This study was supported by NIH R01 CA116395, and the following PHS Cooperative Agreement Grant numbers awarded by the National Cancer Institute, DHHS: CA32102, CA38926, CA63844, CA63845, CA 20319, CA46282, CA46441, CA35261, CA63848, CA67575, CA14028, CA35281, CA128567, CA45560, CA58882, CA13612; CA46368, CA45808, CA58658, CA76447, CA37981, CA04919; CA95860; CA27057, CA42777, CA22433, CA74647, CA86780, CA68183, CA58861, CA45807, CA35192, CA35178, CA58416, CA35176, CA67663, CA35431, CA12644, CA16385, CA11083, CA45377, CA35128, CA35262, CA52654, CA76429, CA58723, CA46113, CA76132, CA45450, CA35119, CA45461, CA21115, CA21076, CA77597, CA25224, CA77202, CCSRI 15469, and in part by Amgen, Inc. Support was also provided by the Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale ™ (DFH), and Drs. Ambrosone, Gralow, Hershman and Hortobagyi are recipients of funding from the Breast Cancer Research Foundation. Dr. Budd serves an advisory at Amgen. Dr. Gralow receives funding from Nevartis, Amgen, Genentech, and Roche. Funding agencies had no involvement in the study design, data collection, analysis and interpretation, or in the writing of the report and submission.

Copyright information

© The Author(s) 2013

Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Authors and Affiliations

  • Gary R. Zirpoli
    • 1
  • Patrick M. Brennan
    • 1
  • Chi-Chen Hong
    • 1
  • Susan E. McCann
    • 1
  • Gregory Ciupak
    • 1
  • Warren Davis
    • 1
  • Joseph M. Unger
    • 2
  • G. Thomas Budd
    • 3
  • Dawn L. Hershman
    • 4
  • Halle C.F. Moore
    • 3
  • James Stewart
    • 5
  • Claudine Isaacs
    • 6
  • Timothy Hobday
    • 7
  • Muhammad Salim
    • 8
  • Gabriel N. Hortobagyi
    • 9
  • Julie R. Gralow
    • 10
  • Kathy S. Albain
    • 11
  • Christine B. Ambrosone
    • 1
  1. 1.Department of Cancer Prevention and ControlRoswell Park Cancer InstituteBuffaloUSA
  2. 2.SWOG Statistical CenterFred Hutchinson Cancer Research CenterSeattleUSA
  3. 3.Department of Solid Tumor OncologyCleveland ClinicClevelandUSA
  4. 4.Department of MedicineColumbia UniversityNew YorkUSA
  5. 5.Department of MedicineBaystate Medical Center, Tufts UniversitySpringfieldUSA
  6. 6.The Fisher Center for Familial Cancer ResearchLombardi Comprehensive Cancer CenterWashingtonUSA
  7. 7.Department of OncologyMayo Clinic College of MedicineRochesterUSA
  8. 8.Allan Blair Cancer CentreReginaCanada
  9. 9.Department of Breast Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  10. 10.Department of MedicineSeattle Cancer Care Alliance, Fred Hutchinson Cancer Research CenterSeattleUSA
  11. 11.Department of MedicineCardinal Bernardin Cancer Center, Loyola University Chicago Stritch School of MedicineMaywoodUSA